title: A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer.
abstract: OBJECTIVE
  A randomized-controlled study of radical radiotherapy for cervical cancer with or without the hypoxic sensitizer, misonidazole was conducted from 1981 to 1984 to investigate its therapeutic benefit.
  
  
  METHODS
  Seventy-three patients were accrued from the Princess Margaret Hospital, and St John Regional Cancer Centre and randomized to either misonidazole (MISO, n = 39) or placebo (P, n = 34) in addition to radiotherapy. MISO was given orally each day 4 h prior to external beam radiation treatment (45Gy to midplane in 20 daily fractions) at a dose of 0.45 g/m(2), as well as during intra-uterine brachytherapy (40Gy).
  
  
  RESULTS
  The 10-year overall survival (OS) for the entire group was 46%, and the disease-free survival (DFS) was 39%. The 10-year OS for patients in the MISO arm was 45%, compared to 49% for the P arm (P = 0.89). The corresponding DFS figures were 36 and 43%, respectively, (P = 0.6). Ten patients (14%) developed severe late complications (grade 3 or 4). The 10-year serious late complication rate was 14% for MISO and 12% for P (P = 0.51).
  
  
  CONCLUSIONS
  Misonidazole failed to improve the outcome of patients with cervix cancer treated with radiotherapy.
authors.affiliation: Department of Radiation Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9.
authors.forename: Philip
authors.initials: P
authors.lastname: Chan
authors.forename: Michael
authors.initials: M
authors.lastname: Milosevic
authors.forename: Anthony
authors.initials: A
authors.lastname: Fyles
authors.forename: John
authors.initials: J
authors.lastname: Carson
authors.forename: Melania
authors.initials: M
authors.lastname: Pintilie
authors.forename: Michael
authors.initials: M
authors.lastname: Rauth
authors.forename: Gillian
authors.initials: G
authors.lastname: Thomas
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy*; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008920:Misonidazole / Q000009:adverse effects / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy*
chemical_list: D011838:Radiation-Sensitizing Agents; D008920:Misonidazole